Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Honey vs EUSOL in Necrotizing Fasciitis Wounds
NCT04831112Completed
- Sponsor
- Dow University of Health Sciences
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Revamil in necrotizing fasciitis (NF) (2 arms), sponsored by Dow University of Health Sciences. Primary endpoint: Early wound healing at 3 weeks. Started Mar 2020; status: completed.
02
Drugs
Revamil
03
Conditions
necrotizing fasciitis (NF)
Beyond the preview
Go deeper on NCT04831112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831112.